[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-542176-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-542176-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","topical-metformin-in-the-treatment-of-melasma-a-preliminary-clinical-trial","Topical metformin in the treatment of melasma - A preliminary clinical trial","","Melasma is a common acquired pigmentary disorder presenting with symmetric facial hyperpigmented macules and patches, and prolonged standard therapy with triple combination cream (TCC) can cause adverse effects. A randomized controlled study evaluated topical 30% metformin lotion versus TCC for 8 weeks in 40 adults, assessing MASI scores, global improvement, and patient satisfaction. All participants completed, with adverse events reported only in the TCC group.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/topical-metformin-in-the-treatment-of-melasma-a-preliminary-clinical-trial/542176/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/topical-metformin-in-the-treatment-of-melasma-a-preliminary-clinical-trial/542176.png","ImageObject",300,407,{"name":42,"@type":43},"kopisore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-10-10",true,{"@type":52,"interactionType":53,"userInteractionCount":22},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What is the purpose of using topical metformin for melasma in this study?","Question",{"text":62,"@type":63},"The study evaluates topical metformin’s safety and efficacy for treating melasma and compares its efficacy with TCC over 8 weeks.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"How was the study designed and what were the treatment groups?",{"text":67,"@type":63},"A randomized controlled study enrolled 40 patients; group 1 received 30% metformin lotion (n=20) and group 2 received TCC (n=20) for 8 weeks.",{"name":69,"@type":60,"acceptedAnswer":70},"What outcomes were used to assess effectiveness and improvement?",{"text":71,"@type":63},"Pigmentation was assessed using the Melasma Area and Severity Index (MASI) at baseline and after 8 weeks, along with a global improvement scale (grades 1–4) and patient satisfaction.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},542176,1791672339,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":22,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":33,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":79,"read_time":123,"preview_page_count":33,"preview_urls":143},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Received: 17 May 2019 | Revised: 26 May 2019 | Accepted: 21 August 2019  \nDOI: 10. 1111/jocd.13145  \nO R I G INAL C O NT R IB UT I O N  \nTopical metformin in the treatment of melasma: A preliminary clinical trial  \nRavikumar Banavase Channakeshavaiah MBBS, MD | Naveen Kumar Andanooru Chandrappa MBBS   \nDepartment of D.V. L, Hassan Institute of Medical Sciences, Hassan, Karnataka, India  \nCorrespondence  \nNaveen Kumar Andanooru Chandrappa, Department of D.V. L, Hassan Institute of Medical Sciences, Hassan‐573201, Karnataka, India.  \nEmail: [naveenac111@gmail.com](naveenac111@gmail.com)  \nAbstract  \nBackground: Melasma is a common acquired pigmentary disorder characterized by symmetric hyperpigmented macules on the face. Triple combination cream (TCC) re‐ mains the gold standard treatment but its prolonged use often causes adverse ef‐ fects. Recently, studies have shown that topical metformin has melanopenic action. Aims: To evaluate the safety and efficacy of topical metformin in the treatment of melasma and to compare its efficacy with TCC (hydroquinone 2% + tretinoin 0.025% + fluocinolone acetonide 0 .01%) .  \nMethods: This was a randomized controlled study conducted on 40 patients with melasma aged more than 18 years. Patients in group 1 (n = 20) were treated with 30% metformin lotion, whereas group 2 patients (n = 20) were treated with TCC for 8 weeks. Pigmentation was assessed using Melasma Area and Severity Index (MASI) at baseline and after 8 weeks. Outcome measures included global improvement scale (grades 1‐4) and patient satisfaction. Safety was assessed according to adverse events and patch testing.  \nResults: All 40 patients completed the study. Out of 20 patients in group 1, 11 showed grade 1 improvement (1% to \u003C25%) and grade 2 (25%‐50%) and grade 3 (>50%‐75%) improvements were seen in one patient each. In group 2, grades 1, 2, 3, and 4 improvements were seen in 14, 2, 1, and 1 patients, respectively. However, the difference was not statistically significant. Adverse events were noted in three patients in group 2 and none in group 1.  \nConclusion: Topical metformin is a novel, safe, and almost as effective modality as TCC to treat melasma.  \nK E Y WO R D S  \nmelasma, metformin, topical, triple combination cream  \n1 | INTRODUCTION  \nMelasma is a common acquired pigmentary disorder that mani‐ fests as symmetric hyperpigmented macules and patches on the face, more frequently affecting women of reproductive age.1 The prevalence of melasma varies between 1. 5% and 33. 3% depend‐ ing on the population. 2,3 The hyperpigmentation in melasma  \nis mainly due to melanocytosis and increased melanogenesis via upregulation of melanin biosynthesis‐related genes such as TYR, microphthalmia‐associated transcription factor (MITF), and tyrosine‐related protein‐1(TYRP1) due to several factors such as genetic predisposition, UV radiation, thyroid disease, and pregnancy, and drugs such as oral contraceptive pills and phenytoin.4‐7  \nJ Cosmet Dermatol. 2019;00:1–[4. wileyonlinelibrary.com/journal/jocd](4. wileyonlinelibrary.com/journal/jocd) © 2019 Wiley Periodicals, Inc. | 1  \n2  \n|  \n CHANNAKESHAVAIAH ANd CHANdRAPPA  \nManagement of melasma is a frustrating experience both for the treating doctors and patients because of its recurrent and often re‐ calcitrant nature. Numerous therapeutic modalities have been tried for this condition such as hydroquinone,8,9 TCC (hydroquinone + ste‐ roid + tretinoin),10‐17 kojic acid, azelaic acid, arbutin, ascorbic acid,  \nchemical peels lasers, tranexamic acid, rucinol, oligopeptides, sily‐,  \nmarin, orchid extracts, and various botanical extracts with variable success rates. However, TCC remains the gold standard, though as‐ sociated with significant adverse effects on long‐term application.  \nHence, the quest for an ideal treatment which can achieve ef‐ fective depigmentation in melasma without any adverse effects has continued. Recently, in vitro studies have shown that topical met‐ formin has mela","cbCaipkdJv7CddQl","https://ap.wps.com/l/cbCaipkdJv7CddQl","pdf",519374,"English","# Abstract\n## Background\n## Aims\n## Methods\n## Results\n## Conclusion\n# Introduction\n# Materials and Methods","[{\"question\":\"What is the purpose of using topical metformin for melasma in this study?\",\"answer\":\"The study evaluates topical metformin’s safety and efficacy for treating melasma and compares its efficacy with TCC over 8 weeks.\"},{\"question\":\"How was the study designed and what were the treatment groups?\",\"answer\":\"A randomized controlled study enrolled 40 patients; group 1 received 30% metformin lotion (n=20) and group 2 received TCC (n=20) for 8 weeks.\"},{\"question\":\"What outcomes were used to assess effectiveness and improvement?\",\"answer\":\"Pigmentation was assessed using the Melasma Area and Severity Index (MASI) at baseline and after 8 weeks, along with a global improvement scale (grades 1–4) and patient satisfaction.\"}]","Topical metformin in the treatment of melasma - A preliminary clinical trial | PDF",[144,148,152,156],{"page_no":22,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/7c8bd967152866d6fe6a411528dce026.webp",983,1291,{"page_no":26,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/1952bb81546dc78cabfe87456599fb46.webp",982,1290,{"page_no":30,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/e3667a9e406acd45483a4e49acace2e6.webp",981,1289,{"page_no":33,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/7f5cb53eb58954a8878809bf365b0049.webp",980,1287]